Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US biopharmaceutical company Shire intends to shut down its Owings Mills drug manufacturing facility as part of its strategy to shift away from in-house manufacturing of drugs, reported Baltimore Sun.
Subscribe to our email newsletter
According the news source, the drug maker plans to close the plant in phases over a period of three years. The closure of the plant is expected to eliminate approximately 260 jobs.
Shire reportedly plans to outsource the drug manufacturing operations that were previously done at the plant to a contract manufacturer based in North Carolina, US. The drug maker hopes to market the space and is believed to be in talks with Baltimore County Department of Economic Development for finding potential takers for the manufacturing site.